Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis in merger talks with Genzyme

Sanofi-aventis has announced that it is in discussions with Genzyme, and has offered to acquire the company for $18.5bn, or $69 a share

Sanofi-aventis (S-A) has announced that it is in discussions with Genzyme, producer of drugs for rare diseases and has offered to acquire the company for $18.5bn, or $69 a share. Genzyme has stated that the figure is too low and the two companies are looking at a way to bridge the valuation gap with a potential contingent value right (CVR) for multiple sclerosis drug alemtuzumab, which the US biotech company plans to brand as Lemtrada.

S-A first sent a letter to Genzyme's management last July. It launched the tender offer, which expires on January 21, after failing to engage Genzyme executives in talks.

Financial advisers for the two companies are discussing the value of a CVR that would take the total Genzyme offer to around $80 per share from $69 at present if it meets certain milestones, giving the US target a total value of $20.7bn.

A representative from S-A said: "Those discussions are continuing and now include representatives from both companies. There remain significant differences on the terms and conditions of the potential CVR and the value of our offer, and there is no guarantee that the parties will come to an agreement."

A contingent value right, or CVR, is often used when buyers and sellers can't agree on a purchase price and usually kicks in after an acquired company meets sales or regulatory targets.

10th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics